Literature DB >> 19065140

A challenge to contemporary management of prostate cancer.

Peter C Albertsen1.   

Abstract

The report by Bill-Axelson et al. challenges current paradigms for diagnosis and treatment of prostate cancer. Contemporary dogma based on 8-year outcomes holds that early diagnosis and treatment improve survival, but after 12 years' follow-up, this study showed no significant difference in overall survival between men randomly allocated radical prostatectomy and those managed with observation. A modest improvement in prostate-cancer-specific survival was only observed in men with a Gleason score of > or =7 who were <65 years of age at diagnosis. After a lead time of 6 years' follow-up, recurrence rates in the radical prostatectomy group were equivalent to those in the observation group. Men diagnosed as having prostate cancer as a result of PSA testing are most likely to benefit from surgery if they have a Gleason score of > or =7 and are aged < or =60 years at diagnosis. Men with a Gleason score of < or =6, especially those >65 years old, are probably best served by active surveillance.

Entities:  

Year:  2008        PMID: 19065140     DOI: 10.1038/ncpuro1270

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  7 in total

1.  Active surveillance for genitourinary cancer: an overview.

Authors:  Laurence Klotz
Journal:  Urol Oncol       Date:  2006 Jan-Feb       Impact factor: 3.498

2.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

3.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

4.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

5.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

Review 6.  Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult.

Authors:  Jenny Donovan; Nicola Mills; Monica Smith; Lucy Brindle; Ann Jacoby; Tim Peters; Stephen Frankel; David Neal; Freddie Hamdy
Journal:  BMJ       Date:  2002-10-05

7.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

  7 in total
  7 in total

1.  [Therapy of local prostate carcinoma. Questions answered by outcome research].

Authors:  D Schnell; H Schön; L Weissbach
Journal:  Urologe A       Date:  2009-09       Impact factor: 0.639

2.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

3.  Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.

Authors:  Morand Piert; Hyunjin Park; Asra Khan; Javed Siddiqui; Hero Hussain; Thomas Chenevert; David Wood; Timothy Johnson; Rajal B Shah; Charles Meyer
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

Review 4.  Treatment strategies for high-risk locally advanced prostate cancer.

Authors:  Seth A Rosenthal; Howard M Sandler
Journal:  Nat Rev Urol       Date:  2010-01       Impact factor: 14.432

5.  Management of high-risk localized prostate cancer.

Authors:  Ariel E Marciscano; Matthew E Hardee; Nicholas Sanfilippo
Journal:  Adv Urol       Date:  2011-11-01

6.  Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness.

Authors:  Ji Chen; Yong Zhao; Xin Li; Peng Sun; Muwen Wang; Ridong Wang; Xunbo Jin
Journal:  Radiol Oncol       Date:  2012-06-19       Impact factor: 2.991

Review 7.  The role of radical prostatectomy in high-risk prostate cancer.

Authors:  Byung Ha Chung
Journal:  Prostate Int       Date:  2013-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.